Bulletin
Investor Alert

London Markets Open in:

Market Pulse Archives

July 7, 2020, 7:22 a.m. EDT

Regeneron's stock gains on $450 million manufacturing deal with U.S. for experimental COVID-19 treatment

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regeneron Pharmaceuticals Inc. (REGN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN -0.16% gained 0.9% in premarket trading on Tuesday after the drugmaker said it received $450 million from the federal government to manufacture and supply its still investigational COVID-19 treatment. The agreement is with the Biomedical Advanced Research and Development Authority and the Department of Defense. Regeneron said Monday that the antibody cocktail candidate is being testing in two Phase 2/3 clinical studies as a treatment for COVID-19; the therapy is also in a Phase 3 trial evaluating whether or not it can prevent someone who has been exposed by a close contact from getting infected with the virus. The company said that if the Food and Drug Administration grants the experimental therapy an emergency use authorization or an approval, "the government has committed to making doses from these lots available to the American people at no cost and would be responsible for their distribution." Regeneron's stock has soared 67.0% since the start of the year, compared with the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.06% , which is down 1.5%.

/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 620.21
-1.00 -0.16%
Volume: 432,739
Aug. 7, 2020 4:00p
P/E Ratio
24.01
Dividend Yield
N/A
Market Cap
$65.99 billion
Rev. per Employee
$906,865
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,351.28
+2.12 +0.06%
Volume: 2.28B
Aug. 7, 2020 5:10p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.